Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Zoetis Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43, while Zoetis Inc trades at $73.8 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| GPTY | ZTS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $156.76 |
52-Week Low | $34.73 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $42.99, up 0.79% on the day, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 at 83.06 suggests overbought conditions. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.28 to $0.38, highlighting its income-focused approach through option premiums on AI and tech equities.
Outlook remains positive due to strong AI theme exposure and income generation, but risks include reliance on semiconductor momentum and potential NAV erosion from option strategies. Investors benefit from high yield but face volatility tied to tech sector performance.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
